TransCelerate CEO Janice Chang wants trials to become part of routine care

Clinical trials are drowning in data. In a TransCelerate/Tufts analysis published in late 2025, phase 3 protocols averaged more than 5.9 million data points, up 67% since 2020. The researchers found that nearly one-third of procedures and associated data were non-core or non-essential. In other words, a good portion of this data does not directly… The post TransCelerate CEO Janice Chang wants trials to become part of routine care appeared first on Drug Discovery and Development.

Continue reading →